Q-omics provides the consensus-scored LY6G5B profile across patient tissues and cancer cell-line models. LY6G5B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LY6G5B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LY6G5B RNA expression shows 19,547 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where LY6G5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6G5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6G5B survival associations across molecular data types. LY6G5B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6G5B RNA expression–survival associations across cancer types. High LY6G5B expression shows unfavorable associations in ACC and KIRC, but favorable associations in BLCA, PAAD, UCS and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LY6G5B RNA expression.
This table summarizes LY6G5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LY6G5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6G5B shows lower tumor expression in BRCA and KICH and higher tumor expression in KIRC, COAD, LIHC and CHOL. The KIRC box plot shows higher LY6G5B RNA expression in tumor versus normal tissue (log2 FC = +0.489, t-test p < 0.001).
This table shows molecular features associated with LY6G5B in patient tissues and cancer cell lines. In patient samples, LY6G5B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LY6G5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
